Figure 7.

Combined treatment of RETAAD skin tumors with topical collagenase and systemic TMZ induces T cell infiltration. Cutaneous tumor-bearing RETAAD mice were treated with Temazolomide (TMZ) or dimethyl sulfoxide (DMSO) vehicle with or without topical collagenase. (A) Flow cytometry analysis of tumor-associated fibroblasts (TAFs) in control and collagenase-treated RETAAD skin tumors. (B) 2-photon high-resolution microscopic images of collagen fibres in skin tumor stroma following collagenase treatment. (C) High magnification images to examine CXCL9 and CXCL10 expression on skin tumor stroma from mice treated with collagenase only, TMZ only or collagenase plus TMZ. (D) Flow cytometry analysis for T cells in skin tumors from RETAAD mice treated with collagenase only, TMZ only or collagenase plus TMZ. Data from panel: (A) are derived from non-treated and collagenase-treated skin tumors pooled from 4 mice per group; (D) are from skin tumors pooled from 4 mice per treatment group. Bars represent mean ± SD. Statistical analyses were performed using the paired two-tailed Student's t-test for (A) and the one-way ANOVA test with Bonferroni's post-test analysis for (D); **p<0.01. Images from (B and C) are representative of 4 independent experiments (n = 4/group). Scale bars in (B) and (C) represent 75 μm and 50 μm, respectively.